Vanguard Personalized Indexing Management LLC Boosts Stake in Allogene Therapeutics, Inc. $ALLO

Vanguard Personalized Indexing Management LLC increased its stake in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 183.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 71,688 shares of the company’s stock after purchasing an additional 46,398 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Allogene Therapeutics were worth $81,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. raised its holdings in Allogene Therapeutics by 177.9% in the first quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company’s stock worth $8,547,000 after purchasing an additional 3,747,397 shares in the last quarter. Frazier Life Sciences Management L.P. grew its position in shares of Allogene Therapeutics by 34.9% in the 1st quarter. Frazier Life Sciences Management L.P. now owns 3,868,750 shares of the company’s stock worth $5,648,000 after buying an additional 1,001,000 shares during the last quarter. Jane Street Group LLC raised its stake in shares of Allogene Therapeutics by 578.7% during the 1st quarter. Jane Street Group LLC now owns 1,116,681 shares of the company’s stock worth $1,630,000 after acquiring an additional 952,158 shares in the last quarter. Aberdeen Group plc raised its stake in shares of Allogene Therapeutics by 138.0% during the 1st quarter. Aberdeen Group plc now owns 867,250 shares of the company’s stock worth $1,266,000 after acquiring an additional 502,868 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in Allogene Therapeutics during the first quarter valued at approximately $706,000. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Stock Performance

NASDAQ:ALLO opened at $1.20 on Monday. The stock has a market capitalization of $266.26 million, a PE ratio of -1.08 and a beta of 0.43. Allogene Therapeutics, Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $3.78. The company has a fifty day moving average of $1.20 and a two-hundred day moving average of $1.26.

Allogene Therapeutics (NASDAQ:ALLO) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.05. Research analysts forecast that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current year.

Insider Buying and Selling at Allogene Therapeutics

In other news, CFO Geoffrey M. Parker sold 36,744 shares of the business’s stock in a transaction dated Tuesday, October 21st. The shares were sold at an average price of $1.26, for a total transaction of $46,297.44. Following the transaction, the chief financial officer owned 1,276,796 shares of the company’s stock, valued at approximately $1,608,762.96. The trade was a 2.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 13.20% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. JMP Securities reaffirmed a “market perform” rating on shares of Allogene Therapeutics in a report on Monday, August 4th. JPMorgan Chase & Co. reissued an “underweight” rating on shares of Allogene Therapeutics in a research report on Friday, October 10th. Wall Street Zen lowered Allogene Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, October 12th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Allogene Therapeutics in a research note on Friday. Nine analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Allogene Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $8.44.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).